Methylation-sensitive high-resolution melting analysis of the USP44 promoter can detect early-stage hepatocellular carcinoma in blood samples
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Hepatocellular carcinoma (HCC) is dangerous cancer that oftenevades early detection because it is asymptomatic and an effectivedetection method is lacking. For people with chronic liverinflammation who are at high risk of developing HCC, a sensitivedetection method for HCC is needed. In a meta-analysisof The Cancer Genome Atlas pan-cancer methylation database,we identified a CpG island in the USP44 promoter that is methylatedspecifically in HCC. We developed methylation-sensitivehigh-resolution melting (MS-HRM) analysis to measure themethylation levels of the USP promoter in cell-free DNA isolatedfrom patients. Our MS-HRM assay correctly identified 40% ofpatients with early-stage HCC, whereas the α-fetoprotein test,which is currently used to detect HCC, correctly identified only25% of early-stage HCC patients. These results demonstratethat USP44 MS-HRM analysis is suitable for HCC surveillance.
Abstract
Hepatocellular carcinoma (HCC) is dangerous cancer that oftenevades early detection because it is asymptomatic and an effectivedetection method is lacking. For people with chronic liverinflammation who are at high risk of developing HCC, a sensitivedetection method for HCC is needed. In a meta-analysisof The Cancer Genome Atlas pan-cancer methylation database,we identified a CpG island in the USP44 promoter that is methylatedspecifically in HCC. We developed methylation-sensitivehigh-resolution melting (MS-HRM) analysis to measure themethylation levels of the USP promoter in cell-free DNA isolatedfrom patients. Our MS-HRM assay correctly identified 40% ofpatients with early-stage HCC, whereas the α-fetoprotein test,which is currently used to detect HCC, correctly identified only25% of early-stage HCC patients. These results demonstratethat USP44 MS-HRM analysis is suitable for HCC surveillance.
참고문헌 (21)
- Rahib L, "Projecting cancer incidence and deaths to 2030 : the unexpected burden of thyroid, liver, and pancreas cancers in the United States", Cancer Res, 74, pp.2913~2921 (2014)
- Tzartzeva K, "Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis : a metaanalysis", Gastroenterology, 154, pp.1706~1718 (2018)
- Inho Kang, "Hepatitis B virus X protein promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells by regulating SOCS1", BMB Reports, 55(5), pp.220~225 (2022), 생화학분자생물학회
- Trevisani F’, "Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease : influence of HBsAg and anti-HCV status", J Hepatol, 34, pp.570~575 (2001)
- Akinyemiju T, "The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level : results from the global burden of disease study 2015", JAMA Oncol, 3, pp.1683~1691 (2017)
- Jepsen P, "Risk for hepatocellular carcinoma in patients with alcoholic cirrhosis : a Danish nationwide cohort study", Ann Intern Med, 156, pp.841~847 (2012)
- Estes C, "Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease", Hepatology, 67, pp.123~133 (2018)
- Sherman M, "Limitations of screening for hepatocellular carcinoma", Hepat Oncol, 1, pp.161~163 (2014)
- Labgaa I, "A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma", Oncogene, 37, pp.3740~3752 (2018)
- Jiang P, "Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients", Proc Natl Acad Sci U S A, 112, pp.1317~1325 (2015)
- Yin CQ, "Liquid biopsy of hepatocellular carcinoma : circulating tumor-derived biomarkers", Dis Markers, 2016, pp.1427849~ (2016)
- 오수민, "From genome sequencing to the discovery of potential biomarkers in liver disease", BMB Reports, 53(6), pp.299~310 (2020), 생화학분자생물학회[DOI]
- Abbosh C, "Early stage NSCLC—challenges to implementing ctDNA-based screening and MRD detection", Nat Rev Clin Oncol, 15, pp.577~586 (2018)
- Stetson D, "Orthogonal comparison of four plasma NGS tests with tumor suggests technical factors are a major source of assay discordance", JCO Precis Oncol, 3, pp.1~9 (2019)
- Lee SM, "Interplay of genetic and epigenetic alterations in hepatocellular carcinoma", Epigenomics, 8, pp.993~1005 (2016)
- von Felden J, "Liquid biopsy in the clinical management of hepatocellular carcinoma", Gut, 69, pp.2025~2034 (2020)
- Kang X, "Serum protein biomarkers screening in HCC patients with liver cirrhosis by ICAT-LCMS", MS, 2010, pp.136, 1151~1159
- Gorgannezhad L, "Circulating tumor DNA and liquid biopsy : opportunities, challenges, and recent advances in detection technologies", Lab Chip, 18, pp.1174~1196 (2018)
- Herman JG, "Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands", Proc Natl Acad Sci U S A, 93, pp.9821~9826 (1996)
- Lan VTT, "Standardization of the methylation‑specific PCR method for analyzing BRCA1and ER methylation", Mol Med Rep, 9, pp.1844~1850 (2014)
- Wojdacz TK, "Methylation-sensitive high-resolution melting", Nat Protoc, 3, pp.1903~1908 (2008)